49549-75-9

Basic information

• Product Name: 3-(1H-Imidazol-4-yl)-1-propanol
• Synonyms: 3-(1H-Imidazol-4-yl)-1-propanol;1H-Imidazole-5-propanol;3-(1H-imidazol-5-yl)propan-1-ol
• CAS NO: 49549-75-9
• Molecular Formula: C₆H₁₀N₂O
• Molecular Weight: 126.16
• Mol File: 49549-75-9.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 371.1±17.0 °C(Predicted)
• Appearance: /
• Density: 1.170±0.06 g/cm3(Predicted)
• PKA: 14.54±0.10(Predicted)
• CAS DataBase Reference: 3-(1H-Imidazol-4-yl)-1-propanol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(1H-Imidazol-4-yl)-1-propanol(49549-75-9)
• EPA Substance Registry System: 3-(1H-Imidazol-4-yl)-1-propanol(49549-75-9)

Safety Data

• Hazardous Substances Data: 49549-75-9(Hazardous Substances Data)

Usage

General Description

3-(1H-Imidazol-4-yl)-1-propanol, also known as imidazole-4-yl-1-propanol, is an organic chemical compound. It contains an imidazole ring, which is a five-membered heterocyclic ring containing two nitrogen atoms. The compound also includes a three-carbon propanol chain. This chemical is commonly used as a reagent and intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It has a variety of potential applications in the pharmaceutical industry, including as a building block for the synthesis of antifungal and antimicrobial agents. Additionally, it may have potential use in the production of surfactants and other specialty chemicals. Overall, 3-(1H-Imidazol-4-yl)-1-propanol is a versatile chemical with a range of potential applications in various industries.

Upstream product

• 5324-21-0 3-bromo-2-methoxy-tetrahydropyran 
• 77287-34-4 formamide 
• 31434-93-2 methyl 3-(4-imidazolyl)propionate 
• 70346-51-9 (E)-methyl 3-(1H-imidazol-4-yl)acrylate 
• 3473-63-0 formamidine acetic acid 
• 7732-18-5 water 
• 52237-38-4 ethyl 3-(imidazol-4'-yl)-propanoate 
• 3465-72-3 urocanic Acid 
• 1074-59-5 3-(imidazol-4-yl)propionic acid 
• 110-87-2 3,4-dihydro-2H-pyran 
• 104-98-3 urocanic acid 

Downstream Products

• 214898-07-4 4-[3-(4-prop-1-ynyl-phenoxy)-propyl]-imidazole-1-carboxylic acid tert-butyl ester 
• 214898-09-6 4-{3-[4-(3,3-dimethyl-but-1-ynyl)-phenoxy]-propyl}-imidazole-1-carboxylic acid tert-butyl ester 
• 214898-08-5 4-[3-(4-pent-1-ynyl-phenoxy)-propyl]-imidazole-1-carboxylic acid tert-butyl ester 
• 214898-10-9 4-[3-(4-trimethylsilanylethynyl-phenoxy)-propyl]-imidazole-1-carboxylic acid tert-butyl ester 
• 152030-49-4 3-(1-trityl-1H-imidazol-4-yl)propan-1-ol 
• 1027314-06-2 1-triphenylmethyl-4-[3-(4-fluorophenoxy)propyl]-1H-imidazole 
• 209599-09-7 4-but-3-ynyl-1-(triphenylmethyl)imidazole 
• 102676-61-9 3-(1-triphenylmethyl-4-imidazolyl)propionaldehyde 
• 1271376-54-5 1-(3-(1H-imidazol-4-yl)propyl)-4-(2-cyclohexylethyl)-1H-1,2,3-triazole 
• 1271376-52-3 1-(3-(1H-imidazol-4-yl)propyl)-4-cyclohexyl-1H-1,2,3-triazole 
• 1271376-46-5 VUF 10192 
• 102676-90-4 5-(3-chloropropyl)-1-<(4-cyanophenyl)methyl>-1H-imidazole hydrochloride 
• 102676-29-9 1-<(4-cyanophenyl)methyl>-1H-imidazole-5-propanol 

Relevant articles and documents

Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease

A series of novel propargylamine-modified pyrimidinylthiourea derivatives (1–3) were designed and synthesized as multifunctional agents for Alzheimer's disease (AD) therapy, and their potential was evaluated through various biological experiments. Among these derivatives, compound 1b displayed good selective inhibitory activity against AChE (vs BuChE, IC50 = 0.324 μM, SI > 123) and MAO-B (vs MAO-A, IC50 = 1.427 μM, SI > 35). Molecular docking study showed that the pyrimidinylthiourea moiety of 1b could bind to the catalytic active site (CAS) of AChE, and the propargylamine moiety interacted directly with the flavin adenine dinucleotide (FAD) of MAO-B. Moreover, 1b demonstrated mild antioxidant ability, good copper chelating property, effective inhibitory activity against Cu2+-induced Aβ1?42 aggregation, moderate neuroprotection, low cytotoxicity, and appropriate blood?brain barrier (BBB) permeability in vitro and was capable of ameliorating scopolamine-induced cognitive impairment in mice. These results indicated that 1b has the potential to be a multifunctional candidate for the treatment of Alzheimer's disease.

Clobenpropit analogs as dual activity ligands for the histamine H3 and H4 receptors: Synthesis, pharmacological evaluation, and cross-target QSAR studies

Previous studies have demonstrated that clobenpropit (N-(4-chlorobenzyl)-S-[3-(4(5)-imidazolyl)propyl]isothiourea) binds to both the human histamine H3 receptor (H3R) and H4 receptor (H4R). In this paper, we describe the synthesis and pharmacological characterization of a series of clobenpropit analogs, which vary in the functional group adjacent to the isothiourea moiety in order to study structural requirements for H3R and H4R ligands. The compounds show moderate to high affinity for both the human H3R and H4R. Furthermore, the changes in the functional group attached to the isothiourea moiety modulate the intrinsic activity of the ligands at the H4R, ranging from neutral antagonism to full agonism. QSAR models have been generated in order to explain the H3R and H4R affinities.

2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION

A 2,3,4,5-tetrahydro-1H-1,5-benzodiazepine derivative represented by the generalformula (1): [Chemical formula 1] (1) or a pharmaceutically acceptable saltthereof. They are useful as a therapeutic/preventive agent for diabetes, diabeticnephropathy, or glomerulosclerosis.